Most treatment-related adverse events (TRAEs) were grade 1 or 2 and related to intravesical instillation consistent with BCG alone - dysuria, pollakiuria, hematuria and micturition urgency.

The most common treatment-emergent adverse events (TEAEs) in the ENVISION trial were dysuria, hematuria ... to patients using a standard urinary catheter in an outpatient setting by a trained ...

UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced new data from the OPTIMA II Phase ...

It is a non-replicating adenovirus vector-based therapy containing the gene interferon alfa-2b, administered locally as a monotherapy by catheter ... increased, hematuria (blood in urine ...

Multiple case reports have discussed late repairs from 7 to 42 days with low rates of erectile dysfunction or penile curvature, albeit with short follow-up. Due ot the nature of the disease, there is ...

This innovative bladder cancer diagnostic kit uses urine samples to achieve 88.8 % sensitivity, promising early detection and reducing the need for cystoscopies.

Furthermore, a recent study that assessed the value of 3D imaging of the bladder for evaluating hematuria showed some ... drainage, and catheter insertion. 21 While it allows for excellent spatial ...